Pharama Company in india

Call Us On :- +91-9427477176

+91-7265835677 

                         +91-9925469962

E-mail us on - sentonssa@gmail.com

Image description

Flingo-200 Tablets 

 
 
 
 

FLINGO – 200 Tablets & FLINGO suspension

 

COMPOSITION

 

FLINGO-200 Tablets
Each film-coated tablet contains Ofloxacin    200 mg

 

FLINGO SUSPENSION   - UPCOMING
Each 5ml contains

Ofloxacin      50 mg

 

INDICATIONS

To reduce the development of drug-resistant bacteria and maintain the effectiveness of ofloxacin tablets and other antibacterial drugs, ofloxacin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy.In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Ofloxacin tablets are indicated for the treatment of adults with mild to moderate infections (unless otherwise indicated) caused by susceptible strains of the designated microorganisms in the infections listed below.

Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae orStreptococcus pneumoniae.

Community-acquired Pneumonia due to Haemophilus influenzae or Streptococcus pneumoniae.

Uncomplicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureusStreptococcus pyogenes, or Proteus mirabilis.

Acute, uncomplicated urethral and cervical gonorrhea due to Neisseria gonorrhoeae.Nongonococcal urethritis and cervicitis due to Chlamydia trachomatis.

Mixed Infections of the urethra and cervix due to Chlamydia trachomatis and Neisseria gonorrhoeae.

Acute pelvic inflammatory disease (including severe infection) due to Chlamydia trachomatisand/or Neisseria gonorrhoeae.

NOTE: If anaerobic microorganisms are suspected of contributing to the infection, appropriate therapy for anaerobic pathogens should be administered.

Uncomplicated cystitis due to Citrobacter diversusEnterobacter aerogenesEscherichia coli, Klebsiella pneumoniaeProteus mirabilis, or Pseudomonas aeruginosa.

Complicated urinary tract infections due to Escherichia coliKlebsiella pneumoniaeProteus mirabilisCitrobacter diversus*, or Pseudomonas aeruginosa*.

Prostatitis due to Escherichia coli.

* = Although treatment of infections due to this organism in this organ system demonstrated a clinically significant outcome, efficacy was studied in fewer than 10 patients.

Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to ofloxacin. Therapy with ofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued.

As with other drugs in this class, some strains of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance.

 

DOSAGE AND ADMINISTRATION

 

Adult Dosage

The usual dose of ofloxacin tablets is 200 mg to 400 mg orally every 12 h as described in the following dosing chart. These recommendations apply to patients with normal renal function (i.e., creatinine clearance > 50 mL/min).

 

Infection†

Unit Dose

Frequency

Duration

Daily Dose

Acute Bacterial Exacerbation of Chronic Bronchitis

400 mg

q12h

10 days

800 mg

Comm. Acquired Pneumonia

400 mg

q12h

10 days

800 mg

Uncomplicated Skin and Skin Structure Infections

400 mg

q12h

10 days

800 mg

Acute, Uncomplicated Urethral and Cervical Gonorrhea

400 mg

single dose

1 days

400 mg

Nongonococcal Cervicitis/Urethritis due to C. trachomatis

300 mg

q12h

7 days

600 mg

Mixed Infection of the urethra and cervix due to C. trachomatis and N. gonorrhoeae

300 mg

q12h

7 days

600 mg

Acute Pelvic Inflammatory Disease

400 mg

q12h

10-14 days

800 mg

Uncomplicated Cystitis due to E. coli or K. pneumoniae

200 mg

q12h

3 days

400 mg

Uncomplicated Cystitis due to other approved pathogens

200 mg

q12h

7 days

400 mg

Complicated UTI's

200 mg

q12h

10 days

400 mg

Prostatitis due to E.Coli

300 mg

q12h

6 weeks

600 mg

† DUE TO THE DESIGNATED PATHOGENS

 

Antacids containing calcium, magnesium, or aluminum; sucralfate; divalent or trivalent cations such as iron; or multivitamins containing zinc; or didanosine should not be taken.

 

Patients with Impaired Renal Function

Dosage should be adjusted for patients with a creatinine clearance < 50 mL/min. After a normal initial dose, dosage should be adjusted as follows:

 

Creatinine Clearance

Maintenance Dose

Frequency

20-50 mL/min

the usual recommended unit dose

q24h

< 20 mL/min

½ the usual recommended unit dose

q24h

 

When only the serum creatinine is known, the following formula may be used to estimate creatinine clearance.

 

Men: Creatinine clearance (mL/min) =

Weight (kg) x (140 – age)
72 x serum creatinine (mg/dL)

Women: 0.85 x the value calculated for men.

The serum creatinine should represent a steady-state of renal function.

 

 

 

 

Patients with Cirrhosis

The excretion of ofloxacin may be reduced in patients with severe liver function disorders (e.g., cirrhosis with or without ascites). A maximum dose of 400 mg of ofloxacin per day should therefore not be exceeded.

 

 

 

CONTRAINDICATIONS

Ofloxacin tablets is contraindicated in persons with a history of hypersensitivity associated with the use of ofloxacin or any member of the quinolone group of antimicrobial agents.

 

PACKAGING INFORMATION

FLINGO-200 Tablets..............        ALU-ALU Pack of 10 Tablets
FLINGO- SUSPENSION ...............60ML pet bottle - Upcoming